Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Deshmukh

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Osteoarthritis and Cartilage|September 11, 2017
A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the kneeV Deshmukh, H Hu, C Barroga, et al.
Georgian Medical News|December 26, 2024
BENNETT'S FRACTURE: A NARRATIVE REVIEW OF CURRENT LITERATUREA Sain, J Chia, N Manzoor, et al.
Osteoarthritis and Cartilage|May 28, 2019
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatmentV Deshmukh, A L O'Green, C Bossard, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 15, 2017
Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 InhibitorFiona Elwood, David J Witter, Jennifer Piesvaux, et al.
Journal of Family Medicine and Primary Care|February 3, 2021
Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panelSanjay Kalra, A K Das, G Priya, et al.
Cancer Research|February 11, 2010
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptorBo-Sheng Pan, Grace K Y Chan, Melissa Chenard, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2007
The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitorsChristopher L Hamblett, Joey L Methot, Dawn M Mampreian, et al.
Journal of Medicinal Chemistry|November 21, 2017
The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic PropertiesTony Siu, Jason Brubaker, Peter Fuller, et al.
Pharmaceutical Research|July 2, 2014
siRNA-mediated knockdown of P450 oxidoreductase in rats: a tool to reduce metabolism by CYPs and increase exposure of high clearance compoundsRob S Burke, Inthirai Somasuntharam, Paul Rearden, et al.
Journal of Medicinal Chemistry|February 6, 2013
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-MetAlan B Northrup, Matthew H Katcher, Michael D Altman, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Osteoarthritis and Cartilage|September 11, 2017
A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the kneeV Deshmukh, H Hu, C Barroga, et al.
Georgian Medical News|December 26, 2024
BENNETT'S FRACTURE: A NARRATIVE REVIEW OF CURRENT LITERATUREA Sain, J Chia, N Manzoor, et al.
Osteoarthritis and Cartilage|May 28, 2019
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatmentV Deshmukh, A L O'Green, C Bossard, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 15, 2017
Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 InhibitorFiona Elwood, David J Witter, Jennifer Piesvaux, et al.
Journal of Family Medicine and Primary Care|February 3, 2021
Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panelSanjay Kalra, A K Das, G Priya, et al.
Cancer Research|February 11, 2010
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptorBo-Sheng Pan, Grace K Y Chan, Melissa Chenard, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2007
The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitorsChristopher L Hamblett, Joey L Methot, Dawn M Mampreian, et al.
Journal of Medicinal Chemistry|November 21, 2017
The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic PropertiesTony Siu, Jason Brubaker, Peter Fuller, et al.
Pharmaceutical Research|July 2, 2014
siRNA-mediated knockdown of P450 oxidoreductase in rats: a tool to reduce metabolism by CYPs and increase exposure of high clearance compoundsRob S Burke, Inthirai Somasuntharam, Paul Rearden, et al.
Journal of Medicinal Chemistry|February 6, 2013
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-MetAlan B Northrup, Matthew H Katcher, Michael D Altman, et al.
Pageof 14